SpringWorks Therapeutics, a US-based drug developer focused on currently incurable diseases, launched yesterday with $103m in series A funding from a consortium that featured pharmaceutical firm Pfizer.
The round also included medical research charity LifeArc as well as investment firm Orbimed and private equity firm Bain Capital, which took part through its Life Sciences fund and its impact investment arm, Double Impact.
SpringWorks Therapeutics was spun out from Pfizer to develop investigational treatments for patients who are currently underserved and…